TheraRadar

Endo

Pre-Approval PRO BETA
🔴

Stale Activity

No new clinical trials started in 2+ years. Activity may be declining or company may be focusing on existing programs. Last trial started: 1/3/2024

49
Total Trials
23
Phase 3
19
Phase 2
0
Recruiting
512
Score

Pipeline by Phase

Phase 3
23
Phase 2
19
Phase 1
5

Therapeutic Focus

Cellulite Edematous Fibrosclerotic Panniculopathy Peyronie's Disease Edematous Fibrosclerotic Panniculopathy (EFP) Adhesive Capsulitis

Clinical Trials (49)

NCT05254457 Phase 3 COMPLETED

Long-Term Safety, Efficacy, and Durability of EN3835 in the Treatment and Retreatment of Plantar Fibromatosis

Started: 2/14/2022

NCT03526549 Phase 3 COMPLETED

Long-Term Study of EN3835 (CCH-aaes) in Edematous Fibrosclerotic Panniculopathy (Cellulite)

Started: 4/26/2018

NCT04170296 Phase 3 COMPLETED

Real World CCH Study in Adult Females With Cellulite

Started: 11/1/2019

NCT02687451 Phase 3 TERMINATED

Clinical Study to Evaluate the Effectiveness, Safety, and Tolerability of Oxymorphone Immediate Release (IR) Oral Liquid in Post Surgical Pediatric Subjects

Started: 4/1/2016

NCT01210352 Phase 3 COMPLETED

Effectiveness, Safety, and Tolerability Study of Oxymorphone Immediate Release (IR) Oral Liquid in Post Surgical Pediatric Subjects

Started: 12/13/2010

NCT04681027 Phase 3 SUSPENDED

Safety, Tolerability, Effectiveness, and Pharmacokinetic Data in Opioid-experienced Children

Started: 3/11/2013

NCT00765856 Phase 3 TERMINATED

Open-Label Safety and Tolerability of Oxymorphone IR and ER in Opioid Tolerant Pediatric Subjects

Started: 11/17/2008

NCT03428750 Phase 3 COMPLETED

Effectiveness and Safety of EN3835 in the Treatment of EFP (Cellulite) in Women

Started: 2/5/2018

NCT03446781 Phase 3 COMPLETED

Effectiveness and Safety of EN3835 in the Treatment of Cellulite in Women

Started: 2/8/2018

NCT00801398 Phase 3 COMPLETED

Open-Label Safety and Tolerability Study of Oxymorphone for Acute Postoperative Pain in Pediatric Subjects.

Started: 2/17/2009

NCT02267460 Phase 3 COMPLETED

An Open-label Study to Assess the Safety and Effectiveness of AA4500 in Combination With the ErecAid® Esteem® Manual Vacuum Therapy System in Treating Men With Peyronie's Disease

Started: 10/1/2014

NCT01228071 Phase 3 COMPLETED

Time to Eugonadal Range, Time to Steady State and Drying Time

Started: 11/1/2010

NCT01685437 Phase 3 COMPLETED

A Phase 3, Open-label Study of the Safety and Effectiveness of AA4500 Administered Twice Per Treatment Cycle for up to Four Treatment Cycles (2 x 4) in Men With Peyronie's Disease

Started: 9/1/2012

NCT01243411 Phase 3 COMPLETED

A Study of AA4500 in Men With Peyronie's Disease

Started: 11/1/2010

NCT01674634 Phase 3 COMPLETED

Safety and Efficacy of Two Concurrent Injections of AA4500 in Adult Subjects With Multiple Dupuytren's Contractures

Started: 9/1/2012

NCT01221623 Phase 3 COMPLETED

Study of AA4500 in the Treatment of Peyronie's Disease

Started: 10/1/2010

NCT01221597 Phase 3 COMPLETED

Study of AA4500 in the Treatment of Peyronie's Disease

Started: 9/1/2010

NCT01310803 Phase 3 TERMINATED

Multi-center Study to Evaluate the Efficacy and Safety of Maintenance Therapy With Valrubicin Versus no Maintenance, in Subjects Treated With Valrubicin Induction for Carcinoma in Situ (CIS) of the Bladder

Started: 5/1/2011

NCT01407068 Phase 3 COMPLETED

Administration of Two Injections for Multiple Dupuytren's Contractures

Started: 9/1/2011

NCT00765323 Phase 3 TERMINATED

Efficacy and Safety Study of Octreotide Implant in Patients With Acromegaly

Started: 9/1/2008

NCT01295060 Phase 3 TERMINATED

Long-term Safety and Efficacy Study of Octreotide Implant in Patients With Acromegaly

Started: 2/1/2011

NCT01206907 Phase 3 WITHDRAWN

Effectiveness, Safety, and Tolerability Study of Oxymorphone Immediate Release (IR) Oral Liquid in Opioid Tolerant Pediatric Subjects

Started: 10/1/2010

NCT05152173 Phase 2 COMPLETED

Efficacy, Safety, and Tolerability, of EN3835 vs Placebo in the Treatment of Plantar Fibromatosis

Started: 11/29/2021

NCT06169319 Phase 2 COMPLETED

A Study to Assess Collagenase Clostridium Histolyticum (CCH) in the Treatment of Plantar Fasciitis (PFA)

Started: 1/3/2024

NCT05419505 Phase 2 COMPLETED

Study of Different Interventions to Reduce Bruising Following CCH-Aaes Treatment for Cellulite of the Buttocks

Started: 6/15/2022

NCT04496167 Phase 2 COMPLETED

Safety and Efficacy of EN3835 in Participants With Frozen Shoulder

Started: 7/29/2020

NCT03632993 Phase 2 COMPLETED

Injection Techniques of Collagenase Clostridium Histolyticum (CCH) for the Treatment of EFP (Cellulite)

Started: 9/18/2018

NCT04580303 Phase 2 COMPLETED

CCH Treatment of Cellulite in the Presence of Dermal Laxity With Comparison Between Two (2) Different Injection Techniques

Started: 10/1/2020

NCT04236635 Phase 2 COMPLETED

Histopathology Following CCH Injection

Started: 12/20/2019

NCT04209530 Phase 2 TERMINATED

Impact of CCH Treatment of Buttock and Thigh Cellulite in Adult Women

Started: 11/20/2019

NCT03329989 Phase 2 COMPLETED

Safety and Effectiveness of EN3835 in the Treatment of EFP in Women

Started: 11/17/2017

NCT02942160 Phase 2 COMPLETED

EN3835 for the Treatment of Edematous Fibrosclerotic Panniculopathy (Commonly Known as Cellulite)

Started: 10/5/2016

NCT02724644 Phase 2 COMPLETED

EN3835 for the Treatment of Edematous Fibrosclerotic Panniculopathy (Commonly Known as Cellulite)

Started: 2/1/2016

NCT02193828 Phase 2 COMPLETED

Phase 2a Dose-Ranging Study to Evaluate Safety and Effectiveness of AA4500 in Treatment of Dupuytren's Disease Nodules

Started: 7/1/2014

NCT01987986 Phase 2 COMPLETED

A Phase 2, Randomized, Double-blind, Placebo Controlled Dose Ranging Study of Repeat Doses of AA4500 for the Treatment of Edematous Fibrosclerotic Panniculopathy

Started: 10/1/2013

NCT00755222 Phase 2 COMPLETED

The Safety and Effectiveness of AA4500 in Subjects With Peyronie's Disease

Started: 8/1/2008

NCT02006719 Phase 2 COMPLETED

Clinical Study for the Treatment of Adhesive Capsulitis of the Shoulder

Started: 11/1/2013

NCT01483963 Phase 2 COMPLETED

AA4500 for the Treatment of Adhesive Capsulitis of the Shoulder

Started: 11/1/2011

NCT01430169 Phase 2 COMPLETED

Pharmacokinetics of a Single Treatment Cycle of AA4500 0.58 mg in Men With Peyronie's Disease

Started: 9/1/2011

NCT00830154 Phase 2 COMPLETED

A Study to Assess the Efficacy and Safety of Pagoclone for Adults With Stuttering

Started: 2/1/2009

NCT04093050 Phase 1 COMPLETED

Safety and Pharmacokinetics of Vasopressin in Healthy Volunteers

Started: 10/10/2019

NCT03675685 Phase 1 COMPLETED

Safety and Pharmacokinetics of a Single Dose of CCH (3.36 mg) in Subjects With EFP

Started: 9/18/2018

NCT01518907 Phase 1 COMPLETED

The Safety, Effectiveness, and Pharmacokinetics of AA4500 for the Treatment of Edematous Fibrosclerotic Panniculopathy (Commonly Known as Cellulite)

Started: 1/1/2012

NCT01774435 Phase 1 COMPLETED

Study in Stabilized Schizophrenic Patients to Evaluate the Pharmacokinetics of Risperidone and 9-Hydroxy (OH)-Risperidone When Risperidone is Administered From a Polyurethane Implant

Started: 10/1/2012

NCT00884715 Phase 1 TERMINATED

Pharmacokinetics, Efficacy and Safety of an Octreotide Implant in Patients With Carcinoid Syndrome

Started: 7/1/2009

NCT04456296 Phase 4 COMPLETED

A Study of the Effect of Testosterone Replacement Therapy on Blood Pressure in Adult Male Participants With Hypogonadism

Started: 6/30/2020

NCT04677712 Phase 4 COMPLETED

Effects of Mitigation Treatments on Bruising of CCH-aaes Treatment of Buttock Cellulite

Started: 12/28/2020

NCT00955110 Phase 4 COMPLETED

Study to Compare Oxymorphone Extended-Release (Opana ER) Versus Oxycodone Controlled-Release (Oxycontin)

Started: 6/1/2009

NCT01498640 Phase 4 COMPLETED

Retreatment of Recurrent Dupuytren's Contractures

Started: 3/1/2012

Drug Candidates

EN3835 Collagenase Clostridium Histolyticum (CCH) Aveed Injectable Product Fortesta Testim CCH-aaes Antifibrinolytic Agent collagenase clostridium histolyticum (CCH) Arnica Gel INhance®
Activity Status: Stale
Last Trial Started: 1/3/2024
Last Trial Ended: 9/30/2024
Trials (12 months): 0
Completed Trials: 40
Data sourced from ClinicalTrials.gov. This company has no FDA-approved drugs.